Vertex Pharmaceuticals Inc
VRTX503.470USD
-6.029-1.18%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
129.36BCap. mercado
PérdidaP/E TTM
Más Datos de Vertex Pharmaceuticals Inc Compañía
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Información de la empresa
Código de la empresaVRTX
Nombre de la empresaVertex Pharmaceuticals Inc
Fecha de salida a bolsaJul 24, 1991
Fundada en1989
Director ejecutivoDr. Reshma Kewalramani
Número de empleados6100
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 24
Dirección50 Northern Avenue
CiudadBOSTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02210
Teléfono16173416393
Sitio Webhttps://www.vrtx.com/
Código de la empresaVRTX
Fecha de salida a bolsaJul 24, 1991
Fundada en1989
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
23.68K
+38.42%
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Ms. Diana L. Mckenzie
Ms. Diana L. Mckenzie
Independent Director
Independent Director
8.63K
+485.29%
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
6.32K
--
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.43K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
23.68K
+38.42%
Desglose de ingresos
Divisa: USDHora de actualización: dom., 6 de abr
Divisa: USDHora de actualización: dom., 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
TRIKAFTA
10.24B
92.91%
Other CF products
781.50M
7.09%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
6.68B
60.66%
Europe
3.45B
31.34%
Other
881.30M
8.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
TRIKAFTA
10.24B
92.91%
Other CF products
781.50M
7.09%
Accionista
Hora de actualización: vie., 21 de feb
Hora de actualización: vie., 21 de feb
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Capital World Investors
11.02%
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
5.57%
State Street Global Advisors (US)
4.66%
Capital Research Global Investors
4.06%
Other
65.69%
Estadísticas de accionistas
Accionista
Proporción
Capital World Investors
11.02%
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
5.57%
State Street Global Advisors (US)
4.66%
Capital Research Global Investors
4.06%
Other
65.69%
Tipo
Accionista
Proporción
Investment Advisor
48.67%
Investment Advisor/Hedge Fund
37.50%
Pension Fund
2.67%
Research Firm
2.17%
Bank and Trust
1.87%
Sovereign Wealth Fund
1.44%
Hedge Fund
1.43%
Individual Investor
0.13%
Insurance Company
0.10%
Other
4.04%
Participación institucional
Hora de actualización: dom., 19 de ene
Hora de actualización: dom., 19 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
2878
247.84M
96.41%
-3.72M
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
2023Q1
2468
250.11M
97.13%
-4.74M
2022Q4
2454
248.59M
96.73%
-7.80M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Capital World Investors
28.33M
11.02%
+1.51M
+5.65%
Dec 31, 2024
The Vanguard Group, Inc.
23.15M
9%
+102.48K
+0.44%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
14.33M
5.57%
-90.57K
-0.63%
Dec 31, 2024
State Street Global Advisors (US)
11.98M
4.66%
+163.16K
+1.38%
Dec 31, 2024
Capital Research Global Investors
10.43M
4.06%
+1.43M
+15.85%
Dec 31, 2024
Fidelity Management & Research Company LLC
9.11M
3.54%
-1.25M
-12.07%
Dec 31, 2024
Wellington Management Company, LLP
5.92M
2.3%
+1.12M
+23.28%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.65M
2.2%
-287.65K
-4.85%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
5.33M
2.07%
+71.48K
+1.36%
Feb 28, 2025
JP Morgan Asset Management
4.62M
1.8%
-403.93K
-8.04%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
VanEck Biotech ETF
10.56%
Tema Neuroscience and Mental Health ETF
9.89%
Invesco Nasdaq Biotechnology ETF
8.48%
ProShares Ultra Nasdaq Biotechnology
8.08%
iShares Biotechnology ETF
7.22%
Indexperts Gorilla Aggressive Growth ETF
6.23%
Natixis Loomis Sayles Focused Growth ETF
4.96%
Franklin Genomic Advancements ETF
4.66%
Amplify AI Powered Equity ETF
4.21%
First Trust NYSE Arca Biotechnology Index Fund
3.65%
Ver más
VanEck Biotech ETF
Proporción10.56%
Tema Neuroscience and Mental Health ETF
Proporción9.89%
Invesco Nasdaq Biotechnology ETF
Proporción8.48%
ProShares Ultra Nasdaq Biotechnology
Proporción8.08%
iShares Biotechnology ETF
Proporción7.22%
Indexperts Gorilla Aggressive Growth ETF
Proporción6.23%
Natixis Loomis Sayles Focused Growth ETF
Proporción4.96%
Franklin Genomic Advancements ETF
Proporción4.66%
Amplify AI Powered Equity ETF
Proporción4.21%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.65%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos